Drugs & Targets FDA approves Hepcludex for chronic hepatitis delta virus infection May 29, 2026Vol.52 No.21
Drugs & Targets FDA grants Orphan Drug designation to oxaliplatin delivered via RenovoCath catheter for pancreatic cancer May 29, 2026Vol.52 No.21
Podcast As FDA’s wheels almost entirely come off, NCI remains sturdy—a cancer moonshot may even be on the horizon May 27, 2026
Cancer Policy FDA’s acting drug chief, acting vaccines chief, and chief of staff ousted in the wake of Makary departure May 22, 2026Vol.52 No.20By Claire Marie Porter
Drugs & Targets FDA approves Enhertu in HER2+ early breast cancer for both neoadjuvant and adjuvant treatment May 22, 2026Vol.52 No.20
Drugs & Targets FDA approves Signatera CDx as a companion diagnostic in muscle-invasive bladder cancer May 22, 2026Vol.52 No.20
Drugs & Targets FDA grants priority review to Hyrnuo in first-line HER2-mutated NSCLC May 22, 2026Vol.52 No.20
Podcast The Cancer History Project debuts first de novo book; meanwhile, FDA snafus continue May 20, 2026
